Brief: RenovoRx Announces Positive New Data From Phase III Clinical Trial Interim Analysis

RenovoRx

30/03/2023 14:50

March 30 (Reuters) - RenovoRx Inc  RNXT.O :
    * RENOVORX ANNOUNCES POSITIVE NEW DATA FROM PHASE III
CLINICAL
TRIAL INTERIM ANALYSIS: 60% SURVIVAL BENEFIT AND FEWER SIDE
EFFECTS THAN SYSTEMIC CHEMOTHERAPY
    * RENOVORX INC - RENOVOGEM PATIENTS HAD GREATER THAN 65%
REDUCTION
IN SIDE EFFECTS
    * RENOVORX INC - WILL BE ADVANCING DISCUSSIONS WITH FDA
ABOUT
EXPEDITING FORWARD PROGRESS FOR RENOVOGEM

Source text for Eikon:  ID:nBw8pp1YYa 
Further company coverage:  RNXT.O 

 ((reuters.briefs@thomsonreuters.com;))